Better Growth Buy: Axsome vs Revolution Medicines
These stocks both scored a win in the first half of the year.
Overview
Axsome Therapeutics (NASDAQ: AXSM) and Revolution Medicines (NASDAQ: RVMD) have offered investors significant growth so far this year. The biotech companies saw their shares soar 34% and 135%, respectively, in the first half. This may have happened as investors, seeking growth beyond the popular theme of artificial intelligence (AI), looked to biotech innovators -- companies with newly launched products or exciting progress in clinical development.
Axsome and Revolution have been stocks to watch in these areas. Axsome has won approval for two products rather recently, and Revolution has announced fantastic phase 3 results for its lead oncology candidate -- one that could transform the treatment of certain cancers. These stocks both make solid buys for an investor looking for growth in the healthcare space. But if you could only buy one, which one should you choose? Let's find out.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
- Why the world’s best-performing stock market this year fell into bear territory
- No Forward-Looking Guidance Needed: Fed Chair Kevin Warsh Just Dropped an Unmistakable Clue About Interest Rates
- The Stock Market Just Made a Move That Warren Buffett Has Called "Playing With Fire." History Shows He's Right.